Teva Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for TEVA PHARMS, and when can generic versions of TEVA PHARMS drugs launch?
TEVA PHARMS has three hundred and twenty approved drugs.
There are three US patents protecting TEVA PHARMS drugs. There are forty-three tentative approvals on TEVA PHARMS drugs.
There are nineteen patent family members on TEVA PHARMS drugs in twelve countries and nine hundred and forty-three supplementary protection certificates in eighteen countries.
Summary for Teva Pharms
International Patents: | 19 |
US Patents: | 3 |
Tradenames: | 264 |
Ingredients: | 259 |
NDAs: | 320 |
Drugs and US Patents for Teva Pharms
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Teva Pharms | LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE | hydrochlorothiazide; losartan potassium | TABLET;ORAL | 077157-002 | Apr 6, 2010 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
Teva Pharms Usa | ARIPIPRAZOLE | aripiprazole | TABLET;ORAL | 078608-001 | Apr 28, 2015 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
Teva Pharms | LEVETIRACETAM | levetiracetam | TABLET;ORAL | 078101-002 | Jan 15, 2009 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Teva Pharms
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Teva Pharms Usa | COPAXONE | glatiramer acetate | INJECTABLE;SUBCUTANEOUS | 020622-003 | Jan 28, 2014 | 6,362,161 | ⤷ Subscribe |
Teva Pharms Intl | AMRIX | cyclobenzaprine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021777-001 | Feb 1, 2007 | 7,829,121 | ⤷ Subscribe |
Teva Pharms Intl | AMRIX | cyclobenzaprine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021777-002 | Feb 1, 2007 | 7,820,203 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for TEVA PHARMS drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | for Injection | 3.5 mg/vial | ➤ Subscribe | 2016-10-26 |
➤ Subscribe | Injection | 40 mg/mL, 1 mL pre-filled syringe | ➤ Subscribe | 2014-01-29 |
➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
➤ Subscribe | Extended-release Capsule | 15 mg and 30 mg | ➤ Subscribe | 2008-08-11 |
➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
➤ Subscribe | Injection | 40 mg/mL, 1 mL pre-filled syringe | ➤ Subscribe | 2014-02-26 |
➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
Premature patent expirations for TEVA PHARMS
Expiration due to failure to pay maintenance fee
Patent Number | Expiration Date |
---|---|
⤷ Subscribe | ⤷ Subscribe |
International Patents for Teva Pharms Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Spain | 2334774 | ⤷ Subscribe |
Japan | 2005508896 | ⤷ Subscribe |
European Patent Office | 2177223 | ⤷ Subscribe |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Teva Pharms Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1746976 | LUC00026 | Luxembourg | ⤷ Subscribe | PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT, SUCH AS IRINOTECAN SUCROSOFATE SALT IN A PEGYLATED LIPOSOME, SUCH AS A LIPOSOME COMPRISING 1,2-DISTEAROYL-SN-PHOSPHATIDYLCHOLINE, CHOLESTEROL AND N-(OMEGA-METHOXY-POLY(ETHYLENE GLYCOL) (MOLECULAR WEIGHT 2000)-OXYCARBONYL)-1,2-DISTEAROYLPHOSPHATIDYL ETHANOLAMINE, E.G. IN THE MOLAR RATIO 3:2:0.015; AUTHORISATION NUMBER AND DATE: EU/1/16/1130 20161018 |
0619813 | SPC/GB10/004 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: PLERIXAFOR IN ALL FORMS PROTECTED BY THE BASIC PATENT; REGISTERED: UK EU/1/09/537/001 20090731; REASON FOR LAPSE: SURRENDERED |
1638574 | 122018000016 | Germany | ⤷ Subscribe | PRODUCT NAME: MIDOSTAURIN ODER EIN SALZ DAVON; REGISTRATION NO/DATE: EU/1/17/1218 20170918 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.